Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas

Presenters: Ann S. LaCasce and Ariela Noy

Although follicular lymphoma (FL) and marginal zone lymphoma (MZL) share similarities, the 2 diseases have distinct biologic differences that affect their presentation and treatment. Stage I disease is more common in MZL than in FL due to marginal zone biology, for example, and stage I MZL is curable by surgery or radiation therapy. Newer therapies for both FL and MZL provide chemotherapy-free options, but they are not identical. Brüton’s tyrosine kinase inhibitors are active in relapsed or refractory MZL but not in FL, for example. CAR T-cell therapy has just been approved for treatment of FL and is an ongoing area of investigation for both diseases.

Disclosures: Dr. LaCasce has disclosed serving on the product/speakers bureau for Research to Practice. Dr. Noy has disclosed serving as a scientific advisor for ADC Therapeutics, Epizyme, EUSA, Janssen Pharmaceutica Products, LP, MorphoSys AG, and TG Therapeutics; receiving honoraria from Medscape and Pharmacyclics; receiving consulting fees from Physicians' Education Resource; and receiving grant/research support from Rafael Pharma.

Correspondence: Ann S. LaCasce, MD, MMSc, Dana-Farber Cancer Institute, 450 Brookline Avenue, M227, Boston, MA 02215. Email: alacasce@partners.org; and Ariela Noy, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: noya@mskcc.org
  • 1.

    Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 2.2022. Accessed March 20, 2022. To view the most recent version, visit NCCN.org

    • Search Google Scholar
    • Export Citation
  • 2.

    Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:11881199.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    TG Therapeutics announces voluntary withdrawal of the BLA/sNDA for U2 to treat patients with CLL and SLL [press release]. Morrisville, NC: Associated Press; April 15, 2022.

    • Search Google Scholar
    • Export Citation
  • 4.

    Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published correction in J Clin Oncol 2018;36:521]. J Clin Oncol 2017;35:38983905.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial [published correction in Lancet Oncol 2021; 22:e239]. Lancet Oncol 2021;22:678689.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:16091618.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Bollard J, Massoma P, Vercherat C, et al. The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors. Oncotarget 2015;6:3673136745.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:14331442.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:91103.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017;129:22242232.

  • 11.

    Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 2020;4:57735784.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res 2021;27:63236332.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020;136:20382050.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Song Y, Zhou K, Zou DH, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study [published online March 18, 2022]. Blood, doi: 10.1182/blood.2021014162

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Lansigan F, Andorsky DJ, Coleman M, et al. Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. Blood 2021;138(Suppl 1):812.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 7506.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 501 501 501
PDF Downloads 227 227 227
EPUB Downloads 0 0 0